3 additional university hospital-level locations-13 secured…. Clinical completion’speed’ by April
“Expected to secure utility and competitiveness… Preparing a follow-up investment plan for the sale of treasury stock in September”
Shinpoong Pharmaceutical Co., Ltd. (CEO, Je-Man Yoo), which is developing a treatment for Corona 19 with the antimalarial drug’Piramax’ (a combination of pyronaridin phosphate and altesunate), is accelerating the development by adding a domestic clinical trial agency.
According to a recent disclosure by the Ministry of Food and Drug Safety to the Integrated Drug Information System, Shinpoong Pharmaceutical has recruited COVID-19 patients from 10 hospitals, including Daegu Guro Hospital, in order to quickly proceed with the phase 2 clinical trial in Korea,’Piramax’, a candidate substance for COVID-19 treatment. Recently, it has secured 13 clinical institutions by adding 3 university hospitals.
In particular, additionally designated clinical institutions are speeding up patient recruitment in connection with the Life Therapy Center, so patient registration is expected to be completed in April.
It is speeding up overseas clinical trials.
In January this year, it was approved by the Philippine Food and Drug Administration, and clinical trials are scheduled to be carried out in six local hospitals. In this clinical trial, the efficacy and safety of’Piramax’ will be confirmed in 402 patients with mild, moderate and severe Corona19. Earlier, in South Africa, clinical trials are underway with 250 patients in five groups in cooperation with the’Malaria Relief Drug Venture Foundation’ (MMV), a non-profit organization that jointly developed’Piramax’.
An official of Shinpoong Pharmaceutical said, “Piramax is a synthetic drug whose antiviral efficacy and combination effect was confirmed in a cell test using human lung cell lines. Expansion of clinical institutions accelerates the development of therapeutic agents, and It is also intended to increase reliability,” he said. “If the clinical trial results in satisfactory results, it is expected to secure high efficacy and competitiveness as an oral treatment that is easy for patients to take.”
In addition, he said, “In order to improve production facilities and secure investment funds for R&D projects, we are preparing future investment plans following the sale of treasury shares in September, and decisions made will be disclosed through public disclosure.”
Copyright © Farm News Unauthorized reproduction and redistribution prohibited